ID   ARAF_HUMAN              Reviewed;         606 AA.
AC   P10398; P07557; Q5H9B2; Q5H9B3;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   15-FEB-2017, entry version 200.
DE   RecName: Full=Serine/threonine-protein kinase A-Raf;
DE            EC=2.7.11.1;
DE   AltName: Full=Proto-oncogene A-Raf;
DE   AltName: Full=Proto-oncogene A-Raf-1;
DE   AltName: Full=Proto-oncogene Pks;
GN   Name=ARAF; Synonyms=ARAF1, PKS, PKS2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3029685; DOI=10.1093/nar/15.2.595;
RA   Beck T.W., Huleihel M., Gunnell M., Bonner T.I., Rapp U.R.;
RT   "The complete coding sequence of the human A-raf-1 oncogene and
RT   transforming activity of a human A-raf carrying retrovirus.";
RL   Nucleic Acids Res. 15:595-609(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=8020955; DOI=10.1006/geno.1994.1125;
RA   Lee J.-E., Beck T.W., Brennscheidt U., DeGennaro L.J., Rapp U.R.;
RT   "The complete sequence and promoter activity of the human A-raf-1 gene
RT   (ARAF1).";
RL   Genomics 20:43-55(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=17535970; DOI=10.1083/jcb.200703195;
RA   Yokoyama T., Takano K., Yoshida A., Katada F., Sun P., Takenawa T.,
RA   Andoh T., Endo T.;
RT   "DA-Raf1, a competent intrinsic dominant-negative antagonist of the
RT   Ras-ERK pathway, is required for myogenic differentiation.";
RL   J. Cell Biol. 177:781-793(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RA   Li W.B., Gruber C., Jessee J., Polayes D.;
RT   "Full-length cDNA libraries and normalization.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 292-589 (ISOFORM 1).
RX   PubMed=3529082; DOI=10.1073/pnas.83.17.6312;
RA   Mark G.E., Seeley T.W., Shows T.B., Mountz J.D.;
RT   "Pks, a raf-related sequence in humans.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:6312-6316(1986).
RN   [9]
RP   INTERACTION WITH NELFD.
RX   PubMed=11952167; DOI=10.1023/A:1014437024129;
RA   Yin X.L., Chen S., Gu J.X.;
RT   "Identification of TH1 as an interaction partner of A-Raf kinase.";
RL   Mol. Cell. Biochem. 231:69-74(2002).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-186, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-318, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   FUNCTION IN TOR SIGNALING.
RX   PubMed=22609986; DOI=10.1038/ncb2507;
RA   Gan X., Wang J., Wang C., Sommer E., Kozasa T., Srinivasula S.,
RA   Alessi D., Offermanns S., Simon M.I., Wu D.;
RT   "PRR5L degradation promotes mTORC2-mediated PKC-delta phosphorylation
RT   and cell migration downstream of Galpha12.";
RL   Nat. Cell Biol. 14:686-696(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-157; SER-162; THR-253;
RP   SER-257 AND SER-269, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-181; SER-186 AND
RP   SER-257, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   STRUCTURE BY NMR OF 19-91.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the N-terminal RAS-binding domain (RBD) in
RT   human A-RAF kinase.";
RL   Submitted (JUL-2005) to the PDB data bank.
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-98; CYS-331 AND ASP-578.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Involved in the transduction of mitogenic signals from
CC       the cell membrane to the nucleus. May also regulate the TOR
CC       signaling cascade. {ECO:0000269|PubMed:22609986}.
CC   -!- FUNCTION: Isoform 2: Serves as a positive regulator of myogenic
CC       differentiation by inducing cell cycle arrest, the expression of
CC       myogenin and other muscle-specific proteins, and myotube
CC       formation. {ECO:0000269|PubMed:22609986}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Interacts with TH1L/NELFD. {ECO:0000269|PubMed:11952167}.
CC   -!- INTERACTION:
CC       P00966:ASS1; NbExp=4; IntAct=EBI-365961, EBI-536842;
CC       P15056:BRAF; NbExp=2; IntAct=EBI-365961, EBI-365980;
CC       Q9UNS2:COPS3; NbExp=3; IntAct=EBI-365961, EBI-350590;
CC       P31327:CPS1; NbExp=3; IntAct=EBI-365961, EBI-536811;
CC       Q12805:EFEMP1; NbExp=3; IntAct=EBI-365961, EBI-536772;
CC       P08238:HSP90AB1; NbExp=6; IntAct=EBI-365961, EBI-352572;
CC       O43187:IRAK2; NbExp=2; IntAct=EBI-365961, EBI-447733;
CC       Q92985:IRF7; NbExp=2; IntAct=EBI-365961, EBI-968267;
CC       P36507:MAP2K2; NbExp=6; IntAct=EBI-365961, EBI-1056930;
CC       Q8IXH7:NELFCD; NbExp=5; IntAct=EBI-365961, EBI-536725;
CC       O95848:NUDT14; NbExp=3; IntAct=EBI-365961, EBI-536866;
CC       Q96KB5:PBK; NbExp=3; IntAct=EBI-365961, EBI-536853;
CC       P14618:PKM; NbExp=2; IntAct=EBI-365961, EBI-353408;
CC       O94906:PRPF6; NbExp=4; IntAct=EBI-365961, EBI-536755;
CC       P53611:RABGGTB; NbExp=3; IntAct=EBI-365961, EBI-536715;
CC       P62070:RRAS2; NbExp=3; IntAct=EBI-365961, EBI-491037;
CC       P31947:SFN; NbExp=2; IntAct=EBI-365961, EBI-476295;
CC       O43615:TIMM44; NbExp=3; IntAct=EBI-365961, EBI-861737;
CC       Q3ZCQ8:TIMM50; NbExp=4; IntAct=EBI-365961, EBI-355175;
CC       P58753:TIRAP; NbExp=2; IntAct=EBI-365961, EBI-528644;
CC       P62258:YWHAE; NbExp=3; IntAct=EBI-365961, EBI-356498;
CC       P63104:YWHAZ; NbExp=5; IntAct=EBI-365961, EBI-347088;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P10398-1; Sequence=Displayed;
CC       Name=2; Synonyms=DA-Raf1;
CC         IsoId=P10398-2; Sequence=VSP_045609, VSP_045610;
CC         Note=Has a wider tissue distribution than isoform 1, and acts as
CC         dominant-negative antagonist.;
CC   -!- TISSUE SPECIFICITY: Predominantly in urogenital tissues.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. RAF subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X04790; CAA28476.1; -; mRNA.
DR   EMBL; L24038; AAA65219.1; -; Genomic_DNA.
DR   EMBL; U01337; AAB03517.1; -; Genomic_DNA.
DR   EMBL; AB158254; BAE66645.1; -; mRNA.
DR   EMBL; BT019864; AAV38667.1; -; mRNA.
DR   EMBL; AL542736; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z84466; CAI42468.1; -; Genomic_DNA.
DR   EMBL; Z84466; CAI42469.1; -; Genomic_DNA.
DR   EMBL; BC002466; AAH02466.1; -; mRNA.
DR   EMBL; M13829; AAB08754.1; -; mRNA.
DR   CCDS; CCDS35232.1; -. [P10398-1]
DR   CCDS; CCDS59164.1; -. [P10398-2]
DR   PIR; A53026; TVHUAF.
DR   RefSeq; NP_001243125.1; NM_001256196.1.
DR   RefSeq; NP_001243126.1; NM_001256197.1. [P10398-2]
DR   RefSeq; NP_001645.1; NM_001654.4. [P10398-1]
DR   RefSeq; XP_011542210.1; XM_011543908.2. [P10398-1]
DR   UniGene; Hs.446641; -.
DR   PDB; 1WXM; NMR; -; A=19-91.
DR   PDB; 2MSE; NMR; -; D=19-91.
DR   PDBsum; 1WXM; -.
DR   PDBsum; 2MSE; -.
DR   ProteinModelPortal; P10398; -.
DR   SMR; P10398; -.
DR   BioGrid; 106864; 91.
DR   DIP; DIP-31374N; -.
DR   IntAct; P10398; 85.
DR   MINT; MINT-88835; -.
DR   STRING; 9606.ENSP00000366244; -.
DR   BindingDB; P10398; -.
DR   ChEMBL; CHEMBL1169596; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   GuidetoPHARMACOLOGY; 1933; -.
DR   iPTMnet; P10398; -.
DR   PhosphoSitePlus; P10398; -.
DR   BioMuta; ARAF; -.
DR   DMDM; 1730068; -.
DR   EPD; P10398; -.
DR   MaxQB; P10398; -.
DR   PaxDb; P10398; -.
DR   PeptideAtlas; P10398; -.
DR   PRIDE; P10398; -.
DR   TopDownProteomics; P10398-1; -. [P10398-1]
DR   DNASU; 369; -.
DR   Ensembl; ENST00000377039; ENSP00000366238; ENSG00000078061. [P10398-2]
DR   Ensembl; ENST00000377045; ENSP00000366244; ENSG00000078061. [P10398-1]
DR   GeneID; 369; -.
DR   KEGG; hsa:369; -.
DR   UCSC; uc031tjj.2; human. [P10398-1]
DR   CTD; 369; -.
DR   DisGeNET; 369; -.
DR   GeneCards; ARAF; -.
DR   HGNC; HGNC:646; ARAF.
DR   HPA; HPA046188; -.
DR   HPA; HPA066326; -.
DR   MalaCards; ARAF; -.
DR   MIM; 311010; gene.
DR   neXtProt; NX_P10398; -.
DR   OpenTargets; ENSG00000078061; -.
DR   PharmGKB; PA24928; -.
DR   eggNOG; KOG0193; Eukaryota.
DR   eggNOG; ENOG410Y4UP; LUCA.
DR   GeneTree; ENSGT00760000118807; -.
DR   HOGENOM; HOG000252972; -.
DR   HOVERGEN; HBG001886; -.
DR   InParanoid; P10398; -.
DR   KO; K08845; -.
DR   PhylomeDB; P10398; -.
DR   TreeFam; TF317006; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   SignaLink; P10398; -.
DR   SIGNOR; P10398; -.
DR   ChiTaRS; ARAF; human.
DR   EvolutionaryTrace; P10398; -.
DR   GeneWiki; ARAF; -.
DR   GenomeRNAi; 369; -.
DR   PRO; PR:P10398; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000078061; -.
DR   CleanEx; HS_ARAF; -.
DR   ExpressionAtlas; P10398; baseline and differential.
DR   Genevisible; P10398; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0007275; P:multicellular organism development; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IBA:GO_Central.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IBA:GO_Central.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032434; P:regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0032006; P:regulation of TOR signaling; IMP:UniProtKB.
DR   CDD; cd00029; C1; 1.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR003116; RBD_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF02196; RBD; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00455; RBD; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50898; RBD; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Kinase; Metal-binding; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1    606       Serine/threonine-protein kinase A-Raf.
FT                                /FTId=PRO_0000085622.
FT   DOMAIN       19     91       RBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00262}.
FT   DOMAIN      310    570       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING      98    144       Phorbol-ester/DAG-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     316    324       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    429    429       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   METAL        99     99       Zinc 1. {ECO:0000250}.
FT   METAL       112    112       Zinc 2. {ECO:0000250}.
FT   METAL       115    115       Zinc 2. {ECO:0000250}.
FT   METAL       125    125       Zinc 1. {ECO:0000250}.
FT   METAL       128    128       Zinc 1. {ECO:0000250}.
FT   METAL       133    133       Zinc 2. {ECO:0000250}.
FT   METAL       136    136       Zinc 2. {ECO:0000250}.
FT   METAL       144    144       Zinc 1. {ECO:0000250}.
FT   BINDING     336    336       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     157    157       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     162    162       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     181    181       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     186    186       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     253    253       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     257    257       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     269    269       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     318    318       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   VAR_SEQ     186    186       S -> R (in isoform 2).
FT                                {ECO:0000303|PubMed:17535970,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_045609.
FT   VAR_SEQ     187    606       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:17535970,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_045610.
FT   VARIANT      98     98       M -> T (in dbSNP:rs56197559).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040375.
FT   VARIANT     331    331       G -> C (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040376.
FT   VARIANT     578    578       E -> D (in dbSNP:rs55852926).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040377.
FT   CONFLICT    368    368       L -> P (in Ref. 8; AAB08754).
FT                                {ECO:0000305}.
FT   CONFLICT    378    378       F -> V (in Ref. 8; AAB08754).
FT                                {ECO:0000305}.
FT   CONFLICT    469    469       S -> P (in Ref. 8; AAB08754).
FT                                {ECO:0000305}.
FT   CONFLICT    478    478       I -> T (in Ref. 8; AAB08754).
FT                                {ECO:0000305}.
FT   STRAND       19     24       {ECO:0000244|PDB:1WXM}.
FT   STRAND       26     28       {ECO:0000244|PDB:1WXM}.
FT   STRAND       30     34       {ECO:0000244|PDB:1WXM}.
FT   HELIX        42     50       {ECO:0000244|PDB:1WXM}.
FT   TURN         51     53       {ECO:0000244|PDB:2MSE}.
FT   STRAND       56     67       {ECO:0000244|PDB:1WXM}.
FT   STRAND       69     72       {ECO:0000244|PDB:1WXM}.
FT   STRAND       74     78       {ECO:0000244|PDB:1WXM}.
FT   HELIX        79     81       {ECO:0000244|PDB:2MSE}.
FT   STRAND       82     84       {ECO:0000244|PDB:2MSE}.
FT   STRAND       85     90       {ECO:0000244|PDB:1WXM}.
SQ   SEQUENCE   606 AA;  67585 MW;  D23E5711304AA468 CRC64;
     MEPPRGPPAN GAEPSRAVGT VKVYLPNKQR TVVTVRDGMS VYDSLDKALK VRGLNQDCCV
     VYRLIKGRKT VTAWDTAIAP LDGEELIVEV LEDVPLTMHN FVRKTFFSLA FCDFCLKFLF
     HGFRCQTCGY KFHQHCSSKV PTVCVDMSTN RQQFYHSVQD LSGGSRQHEA PSNRPLNELL
     TPQGPSPRTQ HCDPEHFPFP APANAPLQRI RSTSTPNVHM VSTTAPMDSN LIQLTGQSFS
     TDAAGSRGGS DGTPRGSPSP ASVSSGRKSP HSKSPAEQRE RKSLADDKKK VKNLGYRDSG
     YYWEVPPSEV QLLKRIGTGS FGTVFRGRWH GDVAVKVLKV SQPTAEQAQA FKNEMQVLRK
     TRHVNILLFM GFMTRPGFAI ITQWCEGSSL YHHLHVADTR FDMVQLIDVA RQTAQGMDYL
     HAKNIIHRDL KSNNIFLHEG LTVKIGDFGL ATVKTRWSGA QPLEQPSGSV LWMAAEVIRM
     QDPNPYSFQS DVYAYGVVLY ELMTGSLPYS HIGCRDQIIF MVGRGYLSPD LSKISSNCPK
     AMRRLLSDCL KFQREERPLF PQILATIELL QRSLPKIERS ASEPSLHRTQ ADELPACLLS
     AARLVP
//
